NEOG · NasdaqGS
Neogen Corporation
Medical Devices · United States
- Market cap (USD)
- US$2.84B
- Trailing P/E
- —
- Forward P/E
- 34.21x
- Quarterly revenue growth
- -0.1%
- Trailing net margin
- -0.9%
- Indicated dividend yield
- —
Snapshot 2026-09-20 · Latest financial period 2026-05-31 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-06 (provider estimate, not issuer-confirmed).
Company background
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Company websiteQ4 FY2026
Go beyond the headline.
Comparable businesses
NEOG peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.
| Metric | NEOGNeogen CorporationSnapshot 2026-09-20Financial period: 2026-05-31 |
|---|---|
| Market capMarket value, converted to USD | US$2.84B |
| Forward P/EProvider forward earnings estimate | 34.21x |
| EV / EBITDAEnterprise value / trailing EBITDA | 36.56x |
| Revenue growthLatest quarter vs prior-year quarter | -0.1% |
| Operating marginLatest reported quarter | 1.4% |
| Free cash flow yieldTrailing cash flow / market cap | 2.5% |
| Net debt / EBITDANet debt / trailing EBITDA | 6.62x |
| Debt / equityTotal debt / positive book equity | 0.39x |
| Trailing P/ETrailing twelve-month earnings | — |
| Price / bookPrice / positive book equity per share | 1.35x |
| EV / salesEnterprise value / trailing revenue | 3.98x |
| Earnings growthLatest quarter vs prior-year quarter | — |
| Gross marginTrailing twelve months | 46.9% |
| Net marginTrailing twelve months | -0.9% |
| Return on equityProvider trailing return; positive equity only | -0.4% |
| Free cash flow marginTrailing free cash flow / revenue | 8.0% |
| Dividend yieldIndicated annual dividend / price | — |
| Earnings payoutProvider trailing dividend payout | 0.0% |
| Current ratioCurrent assets / current liabilities | 3.82x |
| BetaProvider historical market sensitivity | 1.76 |
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for NEOG
Q4 FY20262026-08-01
Neogen (NEOG): Revenue Fell, It Lost Money, and the Stock Jumped 28% — Is NEOG Stock a Buy?
Presentation · 2026-08-01 · YouTube
Short takes Q4 FY2026
NEOG: Revenue Fell, Stock Jumped 28% #shorts
Watch Short on YouTube